OR WAIT null SECS
© 2022 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
November 16, 2021
Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.
November 03, 2021
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
October 20, 2021
Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.
September 28, 2021
Effective Jan. 1 2022, the move brings the price to 2008 levels.
July 29, 2021
The approval allows for substitution at the pharmacy counter for Lantus, its reference product.
July 25, 2021
Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.
July 18, 2021
FDA staff raised safety concerns ahead of the advisory panel hearing.
June 21, 2021
A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.
June 07, 2021
Semaglutide injection is a weekly injection for chronic weight management in adults.
May 04, 2021
The AstraZeneca drug is the first SGLT2 inhibitor approved for chronic kidney disease regardless of whether the patient has diabetes.